Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04842500 · ClinicalTrials.gov registry record · NA

Translational Research to Inform Interventions for Challenging Behavior

A NA study, sponsored by Vanderbilt University.

Completed
Registry status
NA
Development phase
86
Enrollment target

NCT04842500: Completed NA study, sponsored by Vanderbilt University.

NCT04842500 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 86 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04842500, a NA study, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
NA
Development phase
86 participants
Enrollment target

Study Summary

This project is meant to identify relations between the reinforcement histories of 80 adults with intellectual and developmental disabilities (IDD) and the prevalence of extinction bursts. Extinction bursts, or temporary increases in rates and intensities of behavior during extinction, often preclude the inclusion of extinction in intervention packages meant to suppress severe challenging behavior, despite the fact that extinction is often necessary to generate therapeutic outcomes. Study results will provide insight into how researchers can enhance interventions for the severe challenging behavior of individuals with IDD while mitigating the undesirable collateral effects (i.e., extinction bursts) of therapeutic action (i.e., extinction). Expanded access to study results will be made available to those who inquire after all data have been obtained and analyzed.

Primary Outcome

This term describes the highest rate of responding observed during extinction and will be depicted as a proportion of baseline. For example, assuming the mean rate of responding during the final three sessions of baseline is 3 responses per minute (i.e., \[2.8 rpm + 3.2 rpm + 3 rpm\] / 3 = 3 rpm), and the highest rate of responding during a single session of extinction is 3.4 rpm, then peak response rate for this hypothetical individual would be 1.13 (i.e., 3.4 / 3 = 1.13). This value will serve

Interventions

  • BEHAVIORAL Demand Informed Moderator Analysis

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2021-08-01
Est. Completion 2024-05-14
Phase NA
Vanderbilt University

430 total trials

What the finished NCT04842500 record still lists

NCT04842500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 1 intervention - of which Demand Informed Moderator Analysis is the first listed.

NCT04842500 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04842500 about?

NCT04842500 is a clinical study titled "Translational Research to Inform Interventions for Challenging Behavior". This project is meant to identify relations between the reinforcement histories of 80 adults with intellectual and developmental disabilities (IDD) and the prevalence of extinction bursts. Extinction bursts, or temporary increases in rates and intensities of behavior during extinction, often preclud...

What is the current status of trial NCT04842500?

This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2021-08-01. Estimated completion is 2024-05-14.

What interventions are being tested in trial NCT04842500?

The interventions under investigation include: Demand Informed Moderator Analysis (BEHAVIORAL).

Who is sponsoring clinical trial NCT04842500?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04842500's enrollment target sits among peer trials

86 976th of 2000 higher than 1,021 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04842500, the US trial registry maintained by the National Library of Medicine. NCT04842500 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.